Npt2a as a target for treating hyperphosphatemia.

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Hyperphosphatemia, an imbalance in phosphate homeostasis, is linked to cardiovascular issues, especially in chronic kidney disease (CKD).
• Current treatments like oral phosphate binders and dietary restriction are often insufficient for managing elevated plasma phosphate levels in CKD.
• Intestinal phosphate absorption may paradoxically increase with existing therapies.

Purpose of the Study:

• To review recent advancements in targeting the renal sodium/phosphate cotransporter 2a (Npt2a) for managing hyperphosphatemia.
• To discuss the efficacy of Npt2a inhibitors in preclinical models and their impact on phosphate homeostasis.
• To explore potential pleiotropic effects of Npt2a inhibition.

Main Methods:

• Review of recent preclinical studies in rodents investigating Npt2a inhibitors.
• Analysis of the effects of selective Npt2a inhibitors (PF-06869206 and BAY-767) on phosphate excretion and plasma levels.
• Examination of effects on parathyroid hormone (PTH), urinary electrolytes, and fibroblast growth factor 23 (FGF23).

Main Results:

• Selective Npt2a inhibitors significantly increased urinary phosphate excretion in rodent models.
• These inhibitors effectively lowered plasma phosphate and PTH levels.
• Increased urinary excretion of sodium, chloride, and calcium was observed, with some effects noted in models of reduced kidney function.

Conclusions:

• Npt2a inhibition represents a promising therapeutic strategy for hyperphosphatemia, potentially overcoming limitations of current treatments.
• Further research is warranted to understand the role of Npt2a inhibition in phosphate homeostasis and its broader physiological effects.
• Npt2a inhibitors may offer a novel approach for managing phosphate balance in CKD and other conditions.